EspeRare
EspeRare is a Geneva-based nonprofit foundation that develops individualized antisense oligonucleotide therapies for ultra-rare genetic diseases and a repurposed small-molecule therapy for preeclampsia, serving rare disease patients and mothers globally through philanthropic grants and clinical partnerships.
- Company typePrivate
- Founded2013
- HeadquartersPlan-les-ouates, Switzerland
- Headcount1–10
- GTM typeB2B
- OfferingServices
What EspeRare does
EspeRare is a Geneva, Switzerland-based nonprofit foundation founded in 2013 that develops therapies for rare and neglected diseases. The organization operates two primary therapeutic programs: an initiative to expand access in Europe to individualized antisense oligonucleotide (ASO) therapies for ultra-rare and nano-rare genetic diseases, conducted in partnership with the n-Lorem Foundation; and a preeclampsia therapy development project, funded by a Bill & Melinda Gates Foundation Grand Challenges grant, that involves repurposing an oral small molecule originally developed for cardiovascular indications to improve maternal and neonatal health outcomes. Technically, EspeRare's core competency is in ASO chemistry and translational infrastructure for individualized genetic medicines, and as of January 2026 the foundation has added Pacific Biosciences' long-read whole-genome sequencing capability to its development pipeline to accelerate target validation and ASO design.
EspeRare's business model is that of a charitable foundation rather than a commercial biotech. Revenue mechanics center on foundation grants and philanthropic funding, with the Gates Foundation grant representing a major disclosed funding source. The foundation does not appear to charge patients for treatments and does not publicly disclose pricing. Its go-to-market motion is community-led and partnership-driven: EspeRare works with patient advocacy groups, clinical institutions, and strategic partners (notably n-Lorem Foundation and PacBio) to address regulatory, operational, and diagnostic barriers limiting patient access to personalized genetic medicines. Distribution occurs through clinical partnerships with healthcare institutions, initially in Switzerland as proof-of-concept, with planned expansion across the European Union.
The foundation is small (1-10 employees) and serves two distinct end-patient populations: ultra-rare and nano-rare genetic disease patients who lack access to personalized ASO therapies outside the United States, and preeclampsia patients globally. Its customer base of beneficiaries is naturally fragmented, but its operational sustainability is highly dependent on a concentrated set of strategic partners and funders. The organization is actively operating as of early 2026, evidenced by three major partnership and grant announcements within a six-week window.
EspeRare firmographics
Firmographics- Name
- EspeRare
- Website
- https://esperare.org
- Company type
- Private
- Founded year
- 2013
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- EspeRare is a Geneva-based nonprofit foundation that develops individualized antisense oligonucleotide therapies for ultra-rare genetic diseases and a repurposed small-molecule therapy for preeclampsia, serving rare disease patients and mothers globally through philanthropic grants and clinical partnerships.
- Ownership category
- akta.pro rank
EspeRare industry classification
Industry- Product category
- Rare Disease Therapeutics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Voluntary Health Organizations (813212)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Services-Misc Health & Allied Services, Nec (8090)
- akta.pro primary industry
- Antisense Oligonucleotides (ASO) Therapeutics (splice modulation/knockdown) (HLAAADAC)
- akta.pro secondary industry
- Rare Pediatric & Congenital Disorder Therapies (HLAIAIAN)
Keywords
Where EspeRare is headquartered
LocationHeadquarters
- HQ city
- Plan-les-ouates
- HQ country
- Switzerland
- HQ region
- Europe
Offices1 record
Markets served
EspeRare business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations
Revenue model
- Foundation Grants and Philanthropic Funding: EspeRare operates as a nonprofit foundation receiving grants and philanthropic funding to support drug development programs. The Gates Foundation Grand Challenges grant for preeclampsia research represents a major funding source.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels1 record
EspeRare product offering
Product offeringCore offering
EspeRare is a Geneva-based nonprofit biotech foundation that develops therapies for rare and neglected diseases through two primary programs: individualized antisense oligonucleotide (ASO) therapies for ultra-rare genetic diseases (in partnership with the n-Lorem Foundation, expanding access from the US to Europe), and a drug-repurposing program developing an oral small molecule originally used for cardiovascular disorders to treat preeclampsia. The organization funds and coordinates translational infrastructure to deliver these treatments at no cost to patients.
Product overview
EspeRare is a Geneva-based nonprofit biotech organization focused on developing novel therapies for rare genetic diseases and pregnancy complications. The organization operates two primary therapeutic programs: a preeclampsia therapy development project (funded by a Gates Foundation Grand Challenges grant) involving drug repurposing of a cardiovascular small molecule, and a European expansion initiative for individualized antisense oligonucleotide (ASO) therapies for ultra-rare genetic diseases conducted in partnership with n-Lorem Foundation. These programs aim to address unmet medical needs in rare genetic diseases and maternal health through translational infrastructure and patient access initiatives.
Differentiator
Problem solved
Functional benefit
Products and services
- Individualized ASO Therapies for Ultra-Rare Genetic Diseases Personalized antisense oligonucleotide (ASO) therapies developed and delivered to individual patients with ultra-rare and nano-rare genetic diseases through clinical partnerships, primarily serving patients in Switzerland and the EU who currently lack access to such treatments outside the United States.
- Preeclampsia Novel Therapy Development Program A drug-repurposing therapeutic program developing an oral small molecule (originally used for cardiovascular disorders) as a treatment for preeclampsia, a pregnancy complication affecting millions of women and newborns globally. The program is funded by the Gates Foundation and targets improved maternal and neonatal health outcomes.
Quantifiable outcome
- First treatments anticipated within the first year of the European collaboration
- +1 more outcomes
Companies that use EspeRare
Customer profileSegments2 records
Ideal customer profiles2 records
EspeRare technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
EspeRare partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- n-Lorem FoundationcoreMulti-year strategic collaboration to expand access in Europe to n-Lorem's individualized antisense oligonucleotide (ASO) therapies for patients with ultra-rare genetic diseases. The partnership addresses regulatory, operational, and diagnostic barriers limiting access to personalized genetic medicines outside the United States. Initial focus is on treating patients in Switzerland as a proof-of-concept, with subsequent expansion planned across the European Union.
- Pacific Biosciences (PacBio)coreStrategic collaboration to leverage PacBio's long-read whole-genome sequencing technology for developing individualized ASO therapies for ultra-rare genetic diseases. PacBio will donate sequencing reagents and provide scientific expertise for long-read genome analysis. The collaboration aims to integrate long-read WGS earlier in therapeutic development to reduce sequential testing, accelerate target validation, and improve ASO design confidence.
Scale indicators2 records
Recent moves5 records
Expansion highlights4 records
EspeRare competitors and assessment
Company assessmentBroad incumbents
- Ionis Pharmaceuticals: The pioneering commercial ASO therapeutics company, responsible for the chemistry and many of the approved ASO drugs that underlie the individualized-ASO concept. Comparable as the dominant incumbent in antisense oligonucleotide technology that EspeRare's programs ultimately depend on.
- Sarepta Therapeutics: Commercial leader in RNA-targeted therapies for rare genetic diseases, including PMO-based ASO drugs. Relevant as a comparator on rare-disease regulatory strategy, pricing, and infrastructure for genetic-medicine delivery.
- Ultragenyx Pharmaceutical: Commercial rare-disease biotech with a portfolio spanning biologics, ASO, and gene therapy. Comparable in its focus on ultra-rare and rare genetic diseases and its experience building global access infrastructure for low-prevalence therapies.
Regional players
- Fondation Maladies Rares: French nonprofit foundation supporting rare-disease research and patient access in Europe. Comparable as a regional rare-disease foundation that EspeRare could partner with or be benchmarked against when expanding its EU footprint.
Emerging players
- Wave Life Sciences: Clinical-stage developer of stereopure oligonucleotide therapeutics for rare genetic diseases. Comparable as a technology-forward ASO platform pursuing similar indications and patient populations.
Direct peers
- Cure Rare Disease: Nonprofit developing individualized antisense and gene-based therapeutics for ultra-rare neuromuscular diseases. Shares EspeRare's mission of building patient-by-patient genetic medicines through a foundation-led model rather than a traditional commercial pathway.
- ProQR Therapeutics: Clinical-stage biotech developing RNA-editing and antisense oligonucleotide therapies for rare genetic disorders. Comparable as a focused rare-disease ASO developer whose pipeline and target patient populations overlap with EspeRare's ultra-rare mandate.
- n-Lorem Foundation: US-based nonprofit that pioneered the individualized ASO model for nano-rare patients. It is EspeRare's core strategic partner but also the closest analog in mission, technology, and patient access model — the two are effectively the US and European counterparts of the same individualized-ASO delivery system.
Others
- DNDi (Drugs for Neglected Diseases initiative): Nonprofit R&D organization developing treatments for neglected patients using repurposing and partnership-driven models. Comparable as a foundation-led drug developer with an analogous operating playbook to EspeRare's preeclampsia repurposing program.
- EURORDIS – Rare Diseases Europe: European umbrella organization representing rare-disease patient advocacy groups. Comparable as a key ecosystem stakeholder whose policy and patient-advocacy network EspeRare's EU access strategy will depend on.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks5 records
Key highlights6 records
Customer concentration
EspeRare social profiles
Digital presenceEspeRare financial estimates
Financial estimateRevenue estimate
Valuation estimate
EspeRare leadership team
Management profileNumber of profiles
EspeRare funding detail
Funding detailFunding overview
Funding rounds3 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
EspeRare M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about EspeRare
What does EspeRare do?
EspeRare is a Geneva-based nonprofit biotech foundation that develops therapies for rare and neglected diseases through two primary programs: individualized antisense oligonucleotide (ASO) therapies for ultra-rare genetic diseases (in partnership with the n-Lorem Foundation, expanding access from the US to Europe), and a drug-repurposing program developing an oral small molecule originally used for cardiovascular disorders to treat preeclampsia. The organization funds and coordinates translational infrastructure to deliver these treatments at no cost to patients.
Is EspeRare a public or private company?
EspeRare is a private company. It is classified as nonprofit foundation owned and is currently operating.
When was EspeRare founded?
EspeRare was founded in 2013. It employs 1 to 10 people.
Where is EspeRare based?
EspeRare is headquartered in Plan-les-ouates, Switzerland, in the Europe region.
How does EspeRare make money?
One revenue line is on record: foundation Grants and Philanthropic Funding.
Who are EspeRare's main competitors?
Broad incumbents on record are Ionis Pharmaceuticals, Sarepta Therapeutics and Ultragenyx Pharmaceutical. Fondation Maladies Rares is listed as a regional player. Wave Life Sciences is listed as an emerging player. Direct peers are Cure Rare Disease, ProQR Therapeutics and n-Lorem Foundation. Others are DNDi (Drugs for Neglected Diseases initiative) and EURORDIS – Rare Diseases Europe.
Does EspeRare have an API?
No public API is recorded for EspeRare.
What industry is EspeRare in?
EspeRare's product category is Rare Disease Therapeutics. Its primary akta.pro industry code is HLAAADAC, Antisense Oligonucleotides (ASO) Therapeutics (splice modulation/knockdown), with a secondary code of HLAIAIAN, Rare Pediatric & Congenital Disorder Therapies. Its NAICS code is 541714 and its SIC code is 2836.